Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Authors' conclusion
Limited evidence suggests weight reduction of AOMs in older adults, with the best current evidence for the use of semaglutide in older adults with obesity and cardiovascular disease. Larger, more inclusive studies of older adults are needed to guide clinical care and determine the tolerability of AOMs for older adults.
Study context
- Population
- Adults aged ≥65 years with obesity (BMI ≥30 kg/m², or ≥27 kg/m² with one weight-related condition); experimental studies predominantly included patients with prediabetes or CVD6 experimental and 2 observational studies
- Comparison
- Food and Drug Administration (FDA)-approved antiobesity medications vs placebo or baseline
- Outcome
- Weight reduction with AOMs in older adults
Methodological detailsSeven databases searched, Two coauthors extracted data and assessed risk of bias using standardized forms
- Seven databases searched
- Two coauthors extracted data and assessed risk of bias using standardized forms
Pooled result
As reported in the abstract
Weight reduction
Medications studied
7
Sample size of older adults ranged from
13 to 6728
Safety
- Few studies reported on adverse events
Original publication
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review. Obesity (Silver Spring). Published 26 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →